Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 1 of 22

### INTERMEDIATE OF PEPTIDE HYDROLYSIS

$$R^{3} \xrightarrow{H} \stackrel{OH}{\underset{R^{4}}{\bigvee}} \stackrel{R^{1}}{\underset{N}{\bigvee}} R^{2} \qquad R^{3} \xrightarrow{H} \stackrel{OH}{\underset{R^{4}}{\bigvee}} \stackrel{R^{1}}{\underset{N}{\bigvee}} R^{2}$$

HYDROXYETHYLAMINE-BASED INHIBITORS

FIG. 1.

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 2 of 22


Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 3 of 22

## P<sub>3</sub> P<sub>2</sub> P<sub>1</sub> P<sub>1</sub> P<sub>2</sub> P<sub>3</sub>

#### FOUR CONFORMATIONAL FAMILIES

FIG. 3.

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 4 of 22



Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 5 of 22

R<sub>2</sub> SUBSTITUENT

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 6 of 22

$$R_1$$
 SUBSTITUENT 
$$\begin{cases} 0 & \text{NH}_2 \\ \text{o} & \text{o} \\ \text{o} & \text{o} \end{cases}$$

$$H_3 C \xrightarrow{\text{NM}_2} H_2 C \xrightarrow{$$

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 9 of 22

9/22

R3 SUBSTITUENT

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 11 of 22

11/22

# R<sub>2</sub> SUBSTITUENT

FIG. 6B.

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 12 of 22

12/22


13/22

14/22

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 15 of 22

F16. 9.

16/22



Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 17 of 22





FIG. II.

NAME	STRUCTURES	MOLECULAR WEIGHT	Ki (nM)
CEL5-A	OMe CI ON O O O O O O O	839.6	0.7
CEL5-G	CI Br O N N N N O O	697.2	15
EA-I	CI N OH N TO	650	1.9

FIG. 12.

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 19 of 22



F/G. 13.

Atty. Docket No.: 18062G-002020
Applicant: Jonathan A. Ellman et al.
Title: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
USING ASPARTYL PROTEASE INHIBITORS
Sheet 20 of 22




FIG. 14.




FIG. 15A.





FIG. 15B.






FIG. 16B.